PUBLISHER: DelveInsight | PRODUCT CODE: 1159554
PUBLISHER: DelveInsight | PRODUCT CODE: 1159554
DelveInsight's , "Pulmonary embolism - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pulmonary embolism Understanding
Pulmonary embolism: Overview
Pulmonary embolism (PE) occurs when there is a disruption to the flow of blood in the pulmonary artery or its branches by a thrombus that originated somewhere else. In deep vein thrombosis (DVT), a thrombus develops within the deep veins, most commonly in the lower extremities. PE usually occurs when a part of this thrombus breaks off and enters the pulmonary circulation. Very rarely, PE can occur from the embolization of other materials into the pulmonary circulation such as air, fat, or tumor cells. The spectrum of PE and DVT combined is referred to as venous thromboembolism.
"Pulmonary embolism - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary embolism pipeline landscape is provided which includes the disease overview and Pulmonary embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Pulmonary embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary embolism Emerging Drugs
Recombinant staphylokinase contains Forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.
Further product details are provided in the report……..
Pulmonary embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary embolism drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Pulmonary embolism. The companies which have their Pulmonary embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.
DelveInsight's report covers around 5+ products under different phases of clinical development like
Pulmonary embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pulmonary embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary embolism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary embolism drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Pulmonary embolism : Overview
Pipeline Therapeutics
Therapeutic Assessment
Pulmonary embolism - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Recombinant staphylokinase: Supergene
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TS 23: Translational Sciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
YHP1906: Yuhan
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Reteplase: Angde Biotech Pharmaceutical
Drug profiles in the detailed report…..
Inactive Products
Pulmonary embolism Key Companies
Pulmonary embolism Key Products
Pulmonary embolism -Unmet Needs
Pulmonary embolism -Market Drivers and Barriers
Pulmonary embolism -Future Perspectives and Conclusion
Pulmonary embolism Analyst Views
Pulmonary embolism Key Companies
Appendix